Search results for " Chronic obstructive pulmonary disease"

showing 10 items of 51 documents

A year in the life of German patients with COPD: the DACCORD observational study

2016

Roland Buhl,1 Carl-Peter Criée,2 Peter Kardos,3 Claus Vogelmeier,4,5 Nadine Lossi,6 Claudia Mailänder,6 Heinrich Worth7 1Pulmonary Department, Mainz University Hospital, Mainz, 2Department of Sleep and Respiratory Medicine, Evangelical Hospital Göttingen-Weende, Bovenden, 3Group Practice and Centre for Allergy, Respiratory and Sleep Medicine, Red Cross Maingau Hospital, Frankfurt am Main, 4Department of Medicine, Pulmonary, and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, 5German Center for Lung Research, Marburg, 6Clinical Research Primary Care, Novartis Pharma GmbH, Nürnberg, 7Facharztforum F&…

Malemedicine.medical_specialtyPediatricsTime FactorsPulmonary diseaseDiseaseInternational Journal of Chronic Obstructive Pulmonary DiseaseSeverity of Illness IndexSecondary CareSecondary careGerman03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineAmbulatory careRisk FactorsForced Expiratory VolumeGermanyEpidemiologymedicineCOPDHumans030212 general & internal medicineLongitudinal StudiesProspective StudiesLungOriginal ResearchAgedCOPDPrimary Health Carebusiness.industryGeneral MedicineMiddle Agedmedicine.diseaselanguage.human_languageBronchodilator AgentsTreatment Outcome030228 respiratory systemCOPD exacerbationsSpirometryEmergency medicinelanguageDisease ProgressionObservational studyepidemiologybusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

GOLD and the fixed ratio

2012

We thank Dr Vestbo for his interest in our manuscript “Diagnosis of airway obstruction in the elderly: contribution of the SARA study” and for the opportunity to clarify some points. As mentioned in the title and aims, the intent of the paper is to offer a contribution to the open issue of identification of airway obstruction in elderly people.1 We agree with Dr Vestbo about the utility of distinguishing between the clinical and functional aspects of chronic obstructive pulmonary disease (COPD). We stress that, until the term COPD is used, diagnosis needs clinical evidence of a chronic pulmonary disease and functional evidence of airway obstruction. Given that symptoms compatible with COPD …

Malemedicine.medical_specialtyPopulationspirometryDiseaseInternational Journal of Chronic Obstructive Pulmonary Diseaseairflow obstructionchronic obstructive pulmonary diseaseFEV1/FVC ratioPulmonary Disease Chronic ObstructiveEpidemiologymedicineHumansOverdiagnosisMedical prescriptionIntensive care medicineeducationOriginal Researchlcsh:RC705-779COPDeducation.field_of_studybusiness.industryagingGeneral Medicinelung function testslcsh:Diseases of the respiratory systemAirway obstructionrespiratory systemmedicine.diseaseforced expiratory volumerespiratory tract diseasesPhysical therapyFemalebusinesscirculatory and respiratory physiologyInternational Journal of COPD
researchProduct

Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study

2016

Rüdiger Sauer,1 Michaela Hänsel,2 Roland Buhl,3 Roman A Rubin,4 Marcel Frey,5 Thomas Glaab2,3 1Lung Centre Ulm, Ulm, Germany; 2Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; 3Pulmonary Department, Mainz University Hospital, Mainz, Germany; 4Pulmonary Specialist Practice, Wiesbaden, Germany; 5Biometrics, Alcedis GmbH, Gießen, Germany Background: Maintaining and improving physical functioning is key to mitigating the cycle of deconditioning associated with chronic obstructive pulmonary disease (COPD). We evaluated the impact of free combination of the long-acting anticholinergic tiotropium plus the long-acting β2-agonist ol…

Malereal-worldTime FactorsnoninterventionalHealth StatusSeverity of Illness IndexCholinergic AntagonistsPulmonary Disease Chronic Obstructivechemistry.chemical_compound0302 clinical medicinetiotropiumDeconditioningPhysical functioningSurveys and QuestionnairesProspective Studies030212 general & internal medicineLungOriginal ResearchCOPDOlodaterolGeneral MedicineTiotropium bromideMiddle AgedBronchodilator AgentsDrug CombinationsTreatment OutcomeFemalemedicine.drugmedicine.medical_specialtymedicine.drug_classInternational Journal of Chronic Obstructive Pulmonary Diseasechronic obstructive pulmonary disease03 medical and health sciencesAdministration InhalationSeverity of illnessmedicineAnticholinergicphysical functioningHumansTiotropium BromideIntensive care medicineAdrenergic beta-2 Receptor AgonistsAgedolodaterolbusiness.industryNebulizers and VaporizersRecovery of Functionmedicine.diseaseBenzoxazines030228 respiratory systemchemistryPhysical therapyObservational studybusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life

2021

Abstract Background and aims Severe asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS) which worsen patients’ health and increase healthcare spending. Aim of this study was to assess the clinical and economic effect of adding mepolizumab (MEP) for the treatment of these patients. Methods Patients >18 years old, referred to 8 asthma clinics, starting MEP between May 2017 and December 2018, were enrolled and followed-up for 12 months. Information in the 12 months before mepolizumab were collected retrospectively. The evaluation parameters included: OCS use, number of exacerbations/hospitalizations, concomitant therapies, comorbidity, and annual number of workin…

OR Odds RatioPediatricsSevere asthmaExacerbationAnti IL-5; Comorbidities; Mepolizumab; OCS; Pharmacoeconomics; Severe asthmagastroesophageal reflux diseaseSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOICS inhaled corticosteroidRate ratioOCS Oral Corticosteroidslaw.inventionComorbiditiesLAMA long acting muscarinic antagonist0302 clinical medicineRandomized controlled trialfractional nitric oxideInterquartile rangelawlong acting beta 2 agonistOdds RatioImmunology and AllergyRR Rate Ratio030223 otorhinolaryngologyPharmacoeconomicLOS Length of stayLOSIQRLAMAMEP MepolizumabORCISD Standard DeviationMEPPharmacoeconomicsACT Asthma Control TestComorbiditieCI Confidence Intervalsmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyinterquartile rangelong acting muscarinic antagonistImmunologyLABALABA long acting beta 2 agonistComorbidities Mepolizumab OCS Pharmacoeconomics Severe asthma Anti IL-5RRArticleRate Ratiochronic obstructive pulmonary disease03 medical and health sciencesPharmacoeconomicsOCS Oral CorticosteroidAsthma Control TestConfidence IntervalsFeNO fractional nitric oxideRCTs Randomized Controlled TrialmedicineCOPDGERD gastroesophageal reflux diseaseFeNOIQR interquartile rangeMepolizumabSDAsthmaRCTsOral Corticosteroidsbusiness.industryGERDmedicine.diseaseICS inhaled corticosteroidsACTComorbidityRandomized Controlled TrialsCI Confidence IntervalRCTs Randomized Controlled TrialsOCSCOPD chronic obstructive pulmonary disease030228 respiratory systemICSStandard DeviationLength of stayAnti IL-5inhaled corticosteroidslcsh:RC581-607businessMepolizumab
researchProduct

Phospho-p38 MAPK expression in COPD patients and asthmatics and in challenged bronchial epithelium

2015

<b><i>Background:</i></b> The role of mitogen-activated protein kinases (MAPK) in regulating the inflammatory response in the airways of patients with chronic obstructive pulmonary disease (COPD) and asthmatic patients is unclear. <b><i>Objectives:</i></b> To investigate the expression of activated MAPK in lungs of COPD patients and in bronchial biopsies of asthmatic patients and to study MAPK expression in bronchial epithelial cells in response to oxidative and inflammatory stimuli. <b><i>Methods:</i></b> Immunohistochemical expression of phospho (p)-p38 MAPK, p-JNK1 and p-ERK1/2 was measured in bronchial mucosa in pat…

P38 MAPKMaleMAPK/ERK pathwayAsthma phenotypeSMOKERespiratory SystemMitogen-activated protein kinases; p65; Pathology of chronic obstructive pulmonary disease; Chronic obstructive pulmonary disease phenotypes; Asthma phenotypesPathology of chronic obstructive pulmonary diseasep38 Mitogen-Activated Protein KinasesChronic obstructive pulmonary disease phenotypePulmonary Disease Chronic ObstructiveOXIDATIVE STRESSMACROPHAGESRespiratory systemMitogen-activated protein kinasesChronic obstructive pulmonary disease phenotypesMitogen-activated protein kinases; p65; pathology of chronic obstructive pulmonary disease phenotypes; asthma phenotypesCOPDp65KinaseAsthma phenotypes; Chronic obstructive pulmonary disease phenotypes; Mitogen-activated protein kinases; p65; Pathology of chronic obstructive pulmonary disease; Pulmonary and Respiratory MedicineACTIVATED PROTEIN-KINASEInterleukinMiddle AgedImmunohistochemistrypathology of chronic obstructive pulmonary disease phenotypesAsthma phenotypesFemaleLife Sciences & BiomedicinePulmonary and Respiratory Medicinep38 mitogen-activated protein kinasesBlotting WesternINHIBITIONSocio-culturaleBronchiRespiratory MucosaOBSTRUCTIVE PULMONARY-DISEASE1102 Cardiovascular Medicine And HaematologyCell LinemedicineHumansLymphocyte CountInterleukin 8AgedAsthmaScience & Technologybusiness.industryInterleukin-8Transcription Factor RelAPATHWAYSMitogen-activated protein kinasemedicine.diseaseAsthmarespiratory tract diseasesSEVERITYCase-Control StudiesCELLSImmunologybusiness
researchProduct

An international perspective on hospitalized patients with viral community-acquired pneumonia

2019

Background Who should be tested for viruses in patients with community acquired pneumonia (CAP), prevalence and risk factors for viral CAP are still debated. We evaluated the frequency of viral testing, virus prevalence, risk factors and treatment coverage with oseltamivir in patients admitted for CAP. Methods Secondary analysis of GLIMP, an international, multicenter, point-prevalence study of hospitalized adults with CAP. Testing frequency, prevalence of viral CAP and treatment with oseltamivir were assessed among patients who underwent a viral swab. Univariate and multivariate analysis was used to evaluate risk factors. Results 553 (14.9%) patients with CAP underwent nasal swab. Viral CA…

PNEUMONIAMaleMultivariate analysisInternationalityPCV13 pneumococcal conjugate vaccineDatabases FactualHospitalized patientsmedicine.medical_treatmentvirusesCAD coronary artery diseaseTesting030204 cardiovascular system & hematologyMRSA methicillin resistant Staphylococcus aureusPneumònia adquirida a la comunitatRT-PCR reverse transcriptase polymerase chain reactionchemistry.chemical_compound0302 clinical medicineCommunity-acquired pneumoniaTaverne80 and overCommunity-Acquired InfectionViral030212 general & internal medicineProspective StudiesAged 80 and overRIDT rapid influenza diagnostic testCAP community-acquired pneumoniaRSV Respiratory Syncytial virusMiddle AgedICU intensive care unitCommunity-Acquired InfectionsHospitalizationNasal SwabInfectious diseasesFemaleViral swabHumanOseltamivirmedicine.medical_specialtyLogistic ModelCommunity-acquired pneumoniaViral pneumoniaCommunity acquired pneumonia; Influenza; Oseltamivir; Testing; Viral pneumonia; Viral swab; Aged; Aged 80 and over; Antiviral Agents; Community-Acquired Infections; Cross-Sectional Studies; Databases Factual; Female; Hospitalization; Humans; Influenza Human; Internationality; Logistic Models; Male; Medication Adherence; Middle Aged; Oseltamivir; Pneumonia Viral; Prospective StudiesPneumonia ViralAdmissionSettore MED/10 - Malattie Dell'Apparato RespiratorioInfluenzavirusAntiviral AgentsVirusArticleMedication AdherenceHMPV human MetapneumovirusDatabases03 medical and health sciencesLRTI lower respiratory tract infectionOseltamivirInternal medicineInfluenza HumanInternal MedicinemedicineInfluenza virusesHumansHIV Human Immunodeficiency virusPPSV23 pneumococcal polysaccharide vaccineIn patientFactualAgedMechanical ventilationAntiviral AgentCross-Sectional Studiebusiness.industryFEV1 forced expiratory volume in one secondGLIMP global initiative for methicillin-resistant Staphylococcus aureus pneumoniaESBL extended-spectrum beta-lactamasesPneumoniamedicine.diseaseInfluenzaCommunity acquired pneumoniaCI confidence intervalOR odds ratioCross-Sectional StudiesLogistic ModelschemistryCOPD chronic obstructive pulmonary diseasebusinessCommunity acquired pneumonia ; Influenza ; Oseltamivir ; Testing ; Viral pneumonia ; Viral swab
researchProduct

High Flow Nasal Therapy Use in Patients with Acute Exacerbation of COPD and Bronchiectasis: A Feasibility Study

2020

The efficacy and feasibility of high flow nasal therapy (HFNT) use in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and bronchiectasis is unknown. We performed a single-center, single-arm prospective observational study in patients with AECOPD, documented bronchiectasis, pH >= 7.35, respiratory rate (RR) >= 26 breaths/minute despite receiving maximal medical treatment and oxygen via face mask up to 10 L/m. Patients received HFNT (Airvo 2, Fisher & Paykel) at a gas flow of 50 L/min and FIO2 adjusted to maintain SpO(2) >= 92%. Dyspnea, rated by Borg scale, RR, arterial blood gases and mucus production (ranging from 1 to 3) were collected befor…

Pulmonary and Respiratory MedicineMaleAcute exacerbation of chronic obstructive pulmonary diseasemedicine.medical_specialtyExacerbationbronchiectasishumidification03 medical and health sciencesPulmonary Disease Chronic Obstructivebronchiectasi0302 clinical medicineacute respiratory failure bronchiectasis COPD High flow nasal cannula humidification mucus plug sputumRespiratory RateInternal medicineMedicineCannulaHumansCOPDIn patientAcute respiratory failure030212 general & internal medicineProspective StudiesAgedCOPDBronchiectasisacute respiratory failurebusiness.industryOxygen Inhalation TherapysputumCarbon Dioxidemedicine.diseaseSymptom Flare UpHigh flow nasal cannulaMucusDyspnea030228 respiratory systemmucus plugSputumFeasibility StudiesFemalemedicine.symptomBlood Gas AnalysisbusinessHigh flow
researchProduct

Exploring the Relationship between Disease Awareness and Outcomes in Patients with Chronic Obstructive Pulmonary Disease

2020

<b><i>Background:</i></b> Disease awareness is a challenge in the management of chronic obstructive pulmonary disease (COPD). <b><i>Objectives:</i></b> The aim of this analysis was to explore the association between COPD optimal and suboptimal awareness, clinical parameters, and the following patient-reported outcomes: modified Medical Research Council (mMRC), Treatment Satisfaction Questionnaire (TSQM-9), COPD Assessment Test (CAT), Morisky Medication-Taking Adherence Scale (MMAS-4), and Brief Illness Perception Questionnaire (B-IPQ). <b><i>Methods:</i></b> This post hoc analysis of the SAT study included all enrolled …

Pulmonary and Respiratory MedicineMaleHealth Knowledge Attitudes Practicemedicine.medical_specialtyChronic ObstructiveHealth BehaviorClinical InvestigationsPulmonary diseaseSocio-culturaleDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness Indexchronic obstructive pulmonary diseaseTreatment satisfactionIllness perceptionsPulmonary DiseasePulmonary Disease Chronic ObstructiveDiagnostic Self EvaluationInternal medicineSurveys and QuestionnairesPost-hoc analysismedicineSettore MED/10HumansAdherence awareness chronic obstructive pulmonary disease patient-reported outcomesIn patientawarenessPatient Reported Outcome MeasuresAgedCOPDPracticebusiness.industryHealth KnowledgeSelf-Managementmedicine.diseaseSymptom Flare UpAdherence; Awareness; Chronic obstructive pulmonary disease; Patient-reported outcomes; Aged; Female; Health Knowledge Attitudes Practice; Humans; Italy; Male; Patient Reported Outcome Measures; Patient Satisfaction; Severity of Illness Index; Surveys and Questionnaires; Symptom Flare Up; Diagnostic Self Evaluation; Health Behavior; Pulmonary Disease Chronic Obstructive; Self-Management; Treatment Adherence and ComplianceTreatment Adherence and ComplianceItalyPatient SatisfactionAdherencepatient-reported outcomesAttitudesCopd assessment testFemalebusiness
researchProduct

A simple noninvasive pressure–time index at the mouth to measure respiratory load during acute exacerbation of COPD A comparison with normal voluntee…

2003

We assessed the validity of the pressure-time index (PTI) measured at the mouth as a noninvasive and simplified alternative to conventional tension-time index for assessing respiratory load and inspiratory muscle force reserve. PTI was measured within 48 h of hospital admission and at 24 h before discharge in 37 consecutive patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) using the equation PTI = (P(awo)/MIP)(T(I)/T(T)) 100, where P(awo) is the mean airway pressure measured at the mouth, MIP the maximal inspiratory pressure, and T(I)/T(T) the inspiratory time (T(I)) to total cycle length (T(T)) ratio. Controls were 30 normal volunteers with similar anthropome…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyAcute exacerbation of chronic obstructive pulmonary diseaseTime FactorsExacerbationPartial PressureVital CapacityPopulationMean airway pressurechronic obstructive pulmonary diseasePulmonary Disease Chronic ObstructiveForced Expiratory VolumeInternal medicinePressureRespiratory musclemedicineHumansRespiratory systemeducationAgedWork of Breathingeducation.field_of_studyCOPDbusiness.industryRespirationRespiratory diseaseCarbon Dioxidemedicine.diseaseRespiratory MusclesSurgeryOxygenrespiratory muscle fatiguerespiratory loadCardiologyFeasibility StudiesBlood Gas Analysispressure–time indexbusinessRespiratory Medicine
researchProduct

Circulating haemopoietic and endothelial progenitor cells are decreased in COPD

2006

Circulating CD34+ cells are haemopoietic progenitors that may play a role in tissue repair. No data are available on circulating progenitors in chronic obstructive pulmonary disease (COPD). Circulating CD34+ cells were studied in 18 patients with moderate-to-severe COPD (age: mean+/-sd 68+/-8 yrs; forced expiratory volume in one second: 48+/-12% predicted) and 12 controls, at rest and after endurance exercise. Plasma concentrations of haematopoietic growth factors (FMS-like tyrosine kinase 3 (Flt3) ligand, kit ligand), markers of hypoxia (vascular endothelial growth factor (VEGF)) and stimulators of angiogenesis (VEGF, hepatocyte growth factor (HGF)) and markers of systemic inflammation (tu…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyAngiogenesisCD34Antigens CD34cd34Settore MED/10 - Malattie Dell'Apparato RespiratorioSettore BIO/09 - Fisiologiachronic obstructive pulmonary diseaseimmunologyPulmonary Disease Chronic Obstructivecd34+ cellscd34+cellschemistry.chemical_compoundantigensbloodstem cellsInternal medicinegrowth factorsmiddle agedMedicineProgenitor cellhumansCD34+ cells chronic obstructive pulmonary disease exercise growth factors hypoxiacell countpulmonary diseaseCOPDchronic obstructiveexercisehypoxiabusiness.industryaged; antigens; blood; cd34; cd34+ cells; cd34+cells; cell count; chronic obstructive; chronic obstructive pulmonary disease; endothelial cells; exercise; growth factors; hematopoietic stem cells; humans; hypoxia; immunology; middle aged; pulmonary disease; stem cellsHypoxia (medical)medicine.diseaseendothelial cellshematopoietic stem cellsEndothelial stem cellVascular endothelial growth factoragedEndocrinologychemistryHepatocyte growth factormedicine.symptombusinessmedicine.drugEuropean Respiratory Journal
researchProduct